The NEXT-Cue AI software, which incorporates analysis of brain MRI scans, reportedly facilitates prognostic assessments of potential progression from mild cognitive impairment (MCI) to Alzheimer’s disease within five years.
|Articles|October 1, 2007
Scorpion venom stings cancer
Author(s)Don Rauf
While the sting of most scorpions is nonlethal to humans, it's not usually considered health-enhancing either. But the venom could actually prove lifesaving.
Advertisement
While the sting of most scorpions is nonlethal to humans, it's not usually considered health-enhancing either. But the venom could actually prove lifesaving.
Dr. James M. Olson and colleagues at the Fred Hutchinson Cancer Research Center in Seattle attached the peptide chlorotoxin to Cy5.5, a fluorescent molecule that emits near-infrared light. Chlorotoxin, a component of scorpion venom, preferentially binds to cancer cells (Cancer Res 2007;67:6882-6888).
The probe lit up malignant gliomas, medulloblastomas, prostate cancer, intestinal cancer, and sarcomas. Brain tumors as small as 1 mm in diameter and as few as 200 metastatic prostate cancer cells were visualized.
The unique contrast agent shows promise for imaging melanoma and skin, esophageal, cervical, lung, and colon cancers. It binds to cancer cells within minutes after injection, but its signal can be detected for 14 days. Iron oxide-based nanoparticles coated with chlorotoxin imaging are being developed for use with MR.
Advertisement
Related to this article
In a new podcast episode, Amir Iravani, MD, FRACP, discusses emerging dosimetry data from the COMPETE trial for 177Lu-edotreotide and how it may help facilitate more personalized treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
In a recent interview, Phillip Koo, MD, discussed emerging trends with AI, theranostics and empowered patients, and how these developments may lead to challenges and potential opportunities for radiologists and nuclear medicine physicians.
AI has to do more than show potential. It has to deliver measurable results.The Rad AI Outcomes and Market Impact Compendium brings together real-world clinical, operational and financial evidence from health systems, academic medical centers and radiology practices using Rad AI Reporting, Impressions and Continuity.Explore results including 60+ minutes saved per radiologist shift, a 47% reduction in report error rates, 70%+ patient follow-up adherence and >7x ROI — plus, case studies showing how organizations are translating AI into greater capacity, quality and financial performance.See what AI built specifically for radiology can deliver in practice.
Catch up on the top radiology content of the past week.
Assessing breast MRI scans, pathology and clinical data, the AI-powered TumorSight Risk software reportedly provides five- and 10-year risk for breast cancer recurrence for women with HR+, HER2-negative stage I-IIIA breast cancer.
While a new article raises provocative questions about the capability of photon-counting CT (PCCT) to perhaps replace diagnostic ICA, the real revolution with this modality is going beyond stenosis measurement to a renewed focus on the disease of atherosclerosis.
Catch up on the latest imaging research presented at the recent American Society for Radiation Oncology (ASTRO) Annual Meeting.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
2
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
3
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
4
See the Real-World Impact of AI in Radiology
5